Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2019 Jun;17(6):5147-5153.
doi: 10.3892/ol.2019.10167. Epub 2019 Mar 19.

Differential expression of EphA5 protein in gastric carcinoma and its clinical significance

Wei Zhang  1 , Xue Wei  2 , Shuwei Guo  3 , Jiandong Wang  3 , Jing Liu  1 , Hai Wang  2   4
Affiliations

Differential expression of EphA5 protein in gastric carcinoma and its clinical significance

Wei Zhang et al. Oncol Lett. 2019 Jun.

Abstract

The aim of the present study was to evaluate ephrin type-A receptor 5 (EphA5) expression and its clinicopathological significance in gastric cancer. Gastric cancer tissues were analyzed by immunohistochemistry. The association between EphA5 expression and clinicopathological parameters, human epidermal growth factor receptor 2 (HER2) status and Ki-67 proliferation index was statistically analyzed. EphA5 expression was detected in all non-tumor gastric epithelia but was differentially expressed among gastric cancer samples. EphA5 was negatively expressed in 30/110 (27.3%) and positively expressed in 80/110 (72.3%) samples from patients with gastric cancer. EphA5 expression was significantly associated with Lauren classification (P=0.032), lymph node metastasis (P<0.001), HER2 expression (P=0.020) and Ki-67 expression (P=0.005). No significant association was determined between EphA5 expression and age, sex, primary location, depth of invasion and Tumor-Node-Metastasis stage. The present data indicated that EphA5 is differentially expressed in gastric cancer. EphA5 may therefore be a potential therapeutic target and may have clinical utility as a marker for lymph node metastasis in gastric cancer.

Keywords: Ki-67; ephrin type-A receptor 5; gastric cancer; human epidermal growth factor receptor 2.

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
Ephrin type-A receptor 5 expression in non-tumor gastric epithelia and gastric cancer tissues. (A) Positive staining in non-tumor gastric epithelia tissues. (B) Negative expression in gastric cancer tissues. (C) Moderate expression in gastric cancer tissues. (D) Strong expression in gastric cancer tissues. Original magnification, ×400.
Figure 2.
Figure 2.
EphA5 expression is negatively associated with HER2 expression and Ki-67 index in gastric cancer tissues. (A) Hematoxylin and eosin staining. (B) Weak EphA5 staining. (C) Strong HER2 staining. (D) High Ki-67 index. Original magnification, ×400. HER2, human epidermal growth factor receptor 2; EphA5, ephrin type-A receptor 5.
Figure 3.
Figure 3.
EphA5 expression is negatively associated with HER2 and Ki-67 index in gastric cancer tissues. (A) Hematoxylin and eosin staining. (B) Strong EphA5 staining. (C) Negative HER2 staining. (D) Low Ki-67 index. Original magnification, ×400. HER2, human epidermal growth factor receptor 2.
Figure 4.
Figure 4.
HER2 status of gastric cancer specimens confirmed by fluorescence in situ hybridization. (A) Normal gastric epithelia with two green (chromosome 17 centromere) and two orange signals (HER2 gene) in each cell. (B) Low HER2 amplification. The orange signals/green signals were between 1 and 2 in each cell. (C) High HER2 amplification. Orange signals/green signals were >2 in each cell. (D) Polyploidy. The ratio of orange signals/green signals was <2, but orange signals and green signals were >2 in each cell. Original magnification, ×1,000. HER2, human epidermal growth factor receptor 2.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Chen W, Zheng R, Baade PD, Zhang S, Zeng H, Bray F, Jemal A, Yu XQ, He J. Cancer statistics in China, 2015. CA Cancer J Clin. 2016;66:115–132. doi: 10.3322/caac.21338. - DOI - PubMed
    1. Bang YJ, Van Cutsem E, Feyereislova A, Chung HC, Shen L, Sawaki A, Lordick F, Ohtsu A, Omuro Y, Satoh T, et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): A phase 3, open-label, randomised controlled trial. Lancet. 2010;376:687–697. doi: 10.1016/S0140-6736(10)61121-X. - DOI - PubMed
    1. Szöllösi J, Balázs M, Feuerstein BG, Benz CC, Waldman FM. ERBB-2 (HER2/neu) gene copy number, p185HER-2 overexpression, and intratumor heterogeneity in human breast cancer. Cancer Res. 1995;55:5400–5407. - PubMed
    1. Ramieri MT, Murari R, Botti C, Pica E, Zotti G, Alo PL. Detection of HER2 amplification using the SISH technique in breast, colon, prostate, lung and ovarian carcinoma. Anticancer Res. 2010;30:1287–1292. - PubMed
    1. Hofmann M, Stoss O, Shi D, Büttner R, van de Vijver M, Kim W, Ochiai A, Rüschoff J, Henkel T. Assessment of a HER2 scoring system for gastric cancer: Results from a validation study. Histopathology. 2008;52:797–805. doi: 10.1111/j.1365-2559.2008.03028.x. - DOI - PubMed